real-time news and commentary for investors
Thursday, Feb 14
More on Agilent: FY13 guidance is for revenue of $6.9B-$7.1B and EPS of $2.70-$3, below...
More on Agilent: FY13 guidance is for revenue of $6.9B-$7.1B and EPS of $2.70-$3, below consensus of $7.12B and $3.05. Agilent says it's seeing "some volatility in our end-markets." Book-to-bill slightly above 1. Electronic measurement sales -7% Y/Y, worse than FQ4's 5% drop. Chemical analysis -1% (-3% in FQ4), life sciences +2% (flat in FQ4), diagnostics/genomics +4% exc. Dako (+1% in FQ4). All units saw slight Y/Y gross margin drops. R&D and SG&A each +10% Y/Y, above revenue growth. A -8.1% AH, expectations had risen lately. CC at 4:30PM ET (webcast). (PR)